Showing 3191-3200 of 5910 results for "".
- Andreas Pecher to Succeed Dr. Karl Lamprecht as President and CEO of Carl Zeiss AGhttps://modernod.com/news/andreas-pecher-to-succeed-dr-karl-lamprecht-as-president-and-ceo-of-carl-zeiss-ag/2482461/After nearly two decades of leadership at Carl Zeiss AG, Karl Lamprecht, the current President and CEO, has announced that he will not be extending his contract, which is set to expire in the spring of 2025. Andreas Pecher was appointed the company's new President and CEO, effective Apri
- Opthea Completes Manufacturing Milestone for Wet AMD Treatmenthttps://modernod.com/news/opthea-completes-manufacturing-milestone-for-wet-amd-treatment/2482447/Opthea announced the successful completion of its drug substance Process Performance Qualification (PPQ) campaign for sozinibercept, its lead candidate for treating wet age-related macular degeneration (AMD). The PPQ campaign involved the production of three consecutive commercial-scale
- Alkeus Pharmaceuticals Announces Positive Results from SAGA Study of Gildeuretinol Acetate in GA Patientshttps://modernod.com/news/alkeus-pharmaceuticals-announces-positive-results-from-saga-study-of-gildeuretinol-acetate-in-ga-patients-3/2482445/Alkeus Pharmaceuticals announced results from the SAGA study, a phase 3 clinical trial of oral gildeuretinol acetate (ALK-001) in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The study demonstrated a reduction in the growth rate of GA lesions by
- Injectsense Completes First Successful Human Implant of Ultraminiature Intraocular Pressure Sensorhttps://modernod.com/news/injectsense-completes-first-successful-human-implant-of-ultraminiature-intraocular-pressure-sensor/2482413/Injectsense has announced the completion of the first human implant and subsequent wireless IOP measurements using its ultraminiature implantable sensor, which has received FDA breakthrough designation. The IOP-Connect system study is being conducted under the leadership
- Ocugen Receives Health Canada Approval to Initiate Phase 3 Clinical Trial for Retinitis Pigmentosahttps://modernod.com/news/ocugen-receives-health-canada-approval-to-initiate-phase-3-clinical-trial-for-retinitis-pigmentosa/2482410/Ocugen announced that Health Canada has provided a “No Objection Letter” to initiate the phase 3 Limelight clinical trial for OCU400 in Canada. OCU400 is a modifier gene therapy product candidate designed for the treatment of retinitis pigmentosa (RP). "Expand
- Ocuvex Therapeutics Acquires Visiox Pharmaceuticalshttps://modernod.com/news/visiox-pharmaceuticals-merges-with-ocuvex-therapeutics/2482402/Early-stage ophthalmic biotech company Ocuvex Therapeutics announced an agreement to acquire Visiox Pharmaceuticals. Terms of the deal were not disclosed. Visiox's lead asset is Omlonti (omidenepag isopropyl ophthalmic solution 0.002%), an EP2 rece
- Ocumension Therapeutics Secures Deal with Alcon to Expand Dry Eye Treatment Portfolio in Chinahttps://modernod.com/news/ocumension-therapeutics-secures-deal-with-alcon-to-expand-dry-eye-treatment-portfolio-in-china/2482395/China-based ophthalmic pharmaceutical company Ocumension Therapeutics announced an agreement with Alcon under which OcuMension will acquire or secure commercialization rights in China to a portfolio of Alcon’s dry eye treatments and procedural drops, including establishe
- ASCRS Launches Summit Designed to Enhance Refractive Cataract Surgery Practiceshttps://modernod.com/news/ascrs-launches-summit-designed-to-enhance-refractive-cataract-surgery-practices/2482384/In a move to enhance the adoption of advanced-technology IOLs (AT IOLs), the American Society of Cataract & Refractive Surgery (ASCRS) announced a new educational initiative—the ASCRS Business of Refractive Cataract Surgery Summit (BRiCS). The summit aims to equip practices with th
- Johnson & Johnson Invests in Refractive Technology Start-Up TECLenshttps://modernod.com/news/johnson-johnson-invests-in-refractive-technology-start-up-teclens/2482372/Johnson & Johnson closed a transaction to co-lead the Series A funding of TECLens, a start-up developing a nonincisional refractive correction procedure that leverages corneal cross-linking (CXL) to reshape the cornea. Financial terms of the deal were not disclo
- New Data for Susvimo Demonstrates Sustained Efficacy in DME and DRhttps://modernod.com/news/new-data-for-susvimo-demonstrates-sustained-efficacy-in-dme-and-dr/2482365/Genentech and Roche announced 2-year data from the phase 3 Pagoda and Pavilion studies evaluating Susvimo (ranibizumab injection) 100 mg/mL for the treatment of diabetic macular edema (DME) and diabetic retinopathy (DR), respectively. Susvimo, which is being